You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 22, 2018

Clearing the Air on Cannabis Patents

Bangkok Post

The patent system has become an unlikely hot topic in Thailand in light of reports that some overseas pharmaceutical companies have applied for Thai patents for cannabis. The revelations have added more fuel to the ongoing debate about the utility of cannabis, a Thai local plant. The reports have led many to criticize the patent system, questioning whether patent rights may obstruct Thai researchers’ studies on cannabis. It is important not to oversimplify this issue. Such dialogue is extremely important and must be encouraged, but as a patent attorney I find the broader context of the patent system very enlightening in understanding the arguments on both sides.

The most important context of course is the reasoning behind the patent system in the first place. An internationally accepted rationale for patent law is that a patent grants security to an inventor who, through his or her intellect and labor, has conceived an invention that benefits the society. Granting that inventor patent rights prevents others from exploiting the fruit of that inventor’s labor without consent. Simply put, patents prevent anyone from stealing an inventor’s idea. In exchange, the inventor has a duty to make the details (or the “secret trick”) of his or her invention available to the public through the process of patent application. Importantly, a patent is in force for no more than 20 years, after which the knowledge in that patent will become public information for anyone’s free use.

With that in mind, we can begin to look at the specific context of cannabis-based patents.

 

The patent system has become an unlikely hot topic in Thailand in light of reports that some overseas pharmaceutical companies have applied for Thai patents for cannabis. The revelations have added more fuel to the ongoing debate about the utility of cannabis, a Thai local plant. The reports have led many to criticize the patent system, questioning whether patent rights may obstruct Thai researchers’ studies on cannabis. It is important not to oversimplify this issue. Such dialogue is extremely important and must be encouraged, but as a patent attorney I find the broader context of the patent system very enlightening in understanding the arguments on both sides.

The most important context of course is the reasoning behind the patent system in the first place. An internationally accepted rationale for patent law is that a patent grants security to an inventor who, through his or her intellect and labor, has conceived an invention that benefits the society. Granting that inventor patent rights prevents others from exploiting the fruit of that inventor’s labor without consent. Simply put, patents prevent anyone from stealing an inventor’s idea. In exchange, the inventor has a duty to make the details (or the “secret trick”) of his or her invention available to the public through the process of patent application. Importantly, a patent is in force for no more than 20 years, after which the knowledge in that patent will become public information for anyone’s free use.

With that in mind, we can begin to look at the specific context of cannabis-based patents.

Current State of Cannabis Patents in Thailand

A preliminary investigation into the Department of Intellectual Property (DIP) database shows that 91 patent applications have been filed in Thailand relating to the group of chemicals found in cannabis. This search excludes any incidental uses such as traditional medicines and textile industry applications. Among these, only one application has been registered as a Thai patent, and that patent was later revoked. Of the remaining 90 applications, 51 were abandoned without registration. The remaining 39 have been published and are pending substantial examination by the DIP.

It is important to clarify that a patent application is not the same as patent registration. Rights do not exist until an application is registered, and before registration the applicant has no right to sue anyone. Therefore, no one, Thai or foreign, is currently able to sue anyone for infringing a cannabis extract patent in Thailand.

Natural Substances

One hotly debated point is whether or not people should be able to patent “natural substances.” This is an odd argument from a patent attorney’s point of view, because the law already addresses it. Section 9 (1) of the Thai Patent Act B.E. 2522 (1979) expressly prevents “animals, plants or extracts from animals or plants” from being patented. The next logical step is to dig deeper into what that actually means.

The DIP’s Patent Examination Guideline B.E. 2555 (2012), section 1, part 1, page 28, explains that unpatentable “animals, plants or extracts from animals or plants” includes “higher animals and higher plants that are available in nature” and “extracts from animals or plants that have not undergone any man-made substantial processing” (emphasis added). The underlying reason is that a protectable invention must owe its existence to human’s intelligence. The existence of plants, animals, or other things that exist in nature may not be claimed by a human. In cannabis’ case, this law means that the cannabis plant, including its stem, flower, leaf, and crude extracts are not patentable. 

On the other hand, if a human brings a natural thing to be processed by technical means, and thereby causes results and benefits that are not found in the natural state of that thing, then that processed natural thing may be patented. For example, suppose that a certain plant contains Substance A which, in its natural state, does not exhibit any therapeutic effects. Suppose that a researcher later found a way to transform Substance A, or make a pharmaceutical formula containing Substance A, which enables Substance A to perform as an active ingredient for effective treatment of hypertension. The method for transforming that substance, or the pharmaceutical formula, is an invention which may be lawfully patented.

Section 9 (1) must be interpreted with care, and in the proper context of the rationale for patent law, to avoid it leading to slippery slope arguments that negatively affect the patent system. It is true that all human inventions can be traced back to products of nature. For example, many polymers are derived from crude oil, which is found in nature. However, a new petroleum-based polymer that is stronger than steel should be patentable, despite being developed from a product of nature. If Section 9 (1) is interpreted to mean that anything related to nature in any way cannot be patented, then nothing would be patentable.

Preventing the Obstruction of Research

Another hotly debated issue surrounding cannabis patents is a concern that Thai patent registration (which has yet to occur, as noted above) may obstruct medical cannabis research by Thai researchers. This is a rather unlikely scenario for two extremely important reasons.

Firstly, patent protection has a limited scope. Using the Substance A example above, suppose that a patent has been issued for the use of Substance A as a treatment for hypertension (and that the patent has passed all other provisions of the Patent Act). That patent will only cover the use of Substance A for the reasons, and by the means, specified in the patent. The patentee has no right to prevent others from using Substance A for other purposes, for treating other illnesses, or for treating hypertension by a means that is substantially different from what is specified in the patent. In addition, since the patent claims for the “use,” not for Substance A itself (which cannot be patented, as noted above), the patentee is not entitled to prevent others from using or handling Substance A in any other way.

Secondly, research and study are not patent infringement. Section 36, paragraph 2, subsection 1 of the Patent Act provides that “any act for the purpose of study, research, experimentation or analysis” does not infringe upon any patent. This means any study or research that does not compete with the patentee’s business, such as a research conducted by a professor in a medical school, will not expose the researcher to any liability.

The Usefulness of Patents

Finally, in considering these matters in the broader context, it is important to be aware of the general usefulness of the patent system in a broader sense. The patenting system is important for the modern economy. It incentivizes research and development activities, and it allows for knowledge transfer for the public benefit. Patent applications must disclose clear and detailed information about the invention that they relate to, making the complete details of an invention publicly available, from which new ideas and further developments will arise. Researchers are free to study the patents and then seek a technical improvement, which may be patentable in its own right. In addition, when the patent has expired (no longer than 20 years), the once-patented invention will become public knowledge available for anyone’s free use.

The case of cannabis patents is a great opportunity for the Thai public to converse, debate, and consider the benefits and shortcomings of the current patent law system, and hopefully to provide critiques for the betterment of our patent law. However, it is important for any such critique to have a good understanding of the facts on both sides of the argument, before a thorough analysis can take place.

RELATED INSIGHTS​ 

February 25, 2026
Tilleke & Gibbins has updated the Vietnam chapter in the newly released Licensing 2026 guide, published by Lexology Panoramic. The comparative guide provides companies and other interested readers with information on licensing law and practice in various countries around the world. Licensing 2026 provides detailed information on the following topics: Restrictions, laws and licensing arrangements Intellectual property issues: Paris Convention for the Protection of Industrial Property, contesting the validity of licensor’s IP rights, invalidity and expiry of IP rights, security interests, proceedings against third parties, sublicensing, jointly owned IP, first to file, scope of patent protection, trade secrets, copyright Software licensing: Perpetual licensing, legal requirements, user restrictions Royalties and payments, currency conversion, and taxes: Relevant legislation, restrictions, taxation of foreign licensors Competition law issues: Restrictions on trade, legal restrictions, and IP-related court rulings Indemnification, disclaimers, and damages: Prevalence and enforceability of indemnity provisions and contractual waivers of damages Termination: Right to terminate, impact of termination Bankruptcy: Impact of licensee or licensor bankruptcy Dispute resolution: Governing law, arbitration, enforceability, injunctive relief, contractual waivers The Vietnam chapter is available below as a PDF. Readers can gain 30 days of complementary access to the full Licensing 2026 guide and the rest of Lexology Panoramic’s varied offerings through this link.
January 30, 2026
On December 26, 2025, the government of Vietnam promulgated Decree No. 341/2025/ND-CP on administrative sanctions for violations of copyright and related rights (Decree 341), with an effective date of February 15, 2026. The new decree replaces Decree No. 131/2013/ND-CP, as amended, and represents the first comprehensive revision of the administrative enforcement framework in this area in eight years. Legislative Context and Objectives Decree 341 reflects Vietnam’s evolving copyright and related-rights framework, particularly in light of the country’s commitments under bilateral, regional, and multilateral treaties governing the digital environment. While the decree retains a number of provisions from the previous regime, it also introduces significant amendments to infringing acts, penalty thresholds, remedial measures, and enforcement procedures. The primary objectives of the new decree are to (i) enhance the deterrent effect of administrative sanctions; (ii) harmonize sanctions with the 2025 amendments to the Law on Intellectual Property and criminal law principles; and (iii) address enforcement challenges arising from online and cross-border exploitation of copyrighted works. Expanded Scope of Sanctionable Subjects Under Decree 341, administrative sanctions apply not only to Vietnamese entities committing infringing acts within Vietnam, but also to Vietnamese and foreign entities that commit acts of infringement on the internet where the protected content is accessed, consumed, or exploited by users in Vietnam. This expansion reflects the realities of cross-border digital exploitation. However, the decree does not yet provide precise definitions of key terms such as “users” or “consumers” of digital content in Vietnam, which may require further regulatory clarification. Monetary Penalties and Penalty Structure The statutory maximum fines remain unchanged, at VND 250 million for individuals and VND 500 million for organizations, but the penalty framework is substantially restructured. Fines are now calibrated based on three core criteria: (i) the amount of illegal profit obtained; (ii) the level of
January 30, 2026
Vietnam’s Intellectual Property (IP) Law, despite being amended in 2022, underwent another significant revision at the end of 2025. The latest amendment aimed to address five major policy objectives set by the Vietnamese government, including promoting innovation, digital transformation, and international integration. Among the most notable changes in the 2025 IP Law, which takes effect on 1 April 2026, is the expansion of industrial design protection under Article 4.13. The revised definition now includes partial designs and intangible designs, marking a transformative shift in Vietnam’s industrial design regime. This change has particularly significant implications on designs classified under Class 32 of the Locarno Classification—which covers graphic designs, logos, ornamentation, surface patterns, arrangements, and other intangible products. These designs, previously excluded from protection in Vietnam, are now recognized under the new legal framework. Background: Status of Class 32 Designs Before 2026 Th Intellectual Property Office of Vietnam currently applies the 13th edition of the Locarno Classification for industrial design filings. However, not all classes in this system have historically been eligible for protection. Under the 2022 IP Law, Class 32 designs were explicitly excluded based on the following legal grounds: Definition under Article 4.13 (2022 IP Law): “An industrial design is the external appearance of a product or a component for assembly into a complex product, expressed in shapes, lines, colors, or a combination thereof, and visible during the exploitation of the product’s utility or the complex product.” Product requirements under Article 21.2 of Circular 23/2023/TT-BKHCN: A product is defined as an object, a tool, a device, or means, manufactured by industrial or handicraft methods, with clear structure and function. A component for assembly into a complex product must be capable of independent circulation and detachable from the complex product. Based on these definitions, Class 32 designs, such as graphical
December 30, 2025
The Intellectual Property Office of Vietnam (IP Office), with support from the Japan International Cooperation Agency (JICA), is drafting additional annexes to its Guidelines for Patent Examination, focusing on the examination of patent applications in the pharmaceutical and biotechnology sectors. The new annexes are expected to be officially issued in early 2026 as Annexes III and IV, following the successful issuance in 2023 of Annexes I and II addressing computer program-related inventions. The IP Office recently organized a seminar to gather feedback on the draft annexes from intellectual property representatives, academic institutions, research institutes, and other interested parties, emphasizing its intention to receive further constructive opinions to refine the guidelines for pharmaceuticals and biotechnology. Why These Guidelines Matter Patent examination in Vietnam has traditionally relied on the Guidelines for Patent Examination issued under Decision No. 487/QD-SHTT (2010), recently supplemented by Annexes I and II. While these documents provide a solid foundation, they do not fully address practical challenges in examining pharmaceutical and biotech inventions, particularly issues related to clarity, sufficiency of disclosure, enablement, features of function and utility, combination therapies, and inventions involving artificial intelligence (AI) applications in these fields. Annexes III and IV aim to close these gaps by introducing structured principles and illustrative examples. Guidance on Patent Specification Requirements Annex III provides detailed guidance on the requirements for patent specifications in pharmaceuticals and biotechnology, covering two main parts: Part A addresses sufficiency of disclosure, clarity of specifications, and consistency between claims and descriptions. Part B covers inventions related to Markush-type compounds, claims containing exclusion statements (disclaimers), and additional experimental data submitted during examination. The Guidelines outline specific disclosure requirements for subject matters such as compounds, formulations, pharmaceutical compositions, genes, polypeptides, proteins, vectors, transgenic organisms, modified organisms, and hybrid cells. Annex III emphasizes that disclaimers are not accepted